Objective. We aimed to investigate the role of caveolin-1 in papillary thyroid carcinoma pathogenesis.
Subjects and Methods. We evaluated the expression of caveolin-1 in papillary thyroid carcinoma (PTC) by Western blot (WB) and compared the findings with immunohistochemical (IHC) expression of both epithelial and stromal caveolin-1 on the corresponding histological specimens. The results were related to clinicopathological features and BRAF mutation status.
Results. Caveolin-1 expression was found in malignant thyroid epithelium and more abundantly in tumor stroma but varied in both compartments within and between PTC subtypes. Caveolin-1 expression in the epithelium was more intense in classical PTC than in the other histological types. On the contrary, stromal caveolin-1 expression was stronger in the follicular, solid, and trabecular PTC variants than in classical PTC. Trends for down-regulation of caveolin-1 expression in epithelium and up-regulation in stroma from the classical via follicular to the solid variant were observed. The relation of WB and IHC results with clinicopathological parameters showed lower caveolin-1 tissue content in BRAF mutated tumors (P \ .05), a positive correlation of epithelial caveolin-1 expression with lymph node metastasis (P \ .05), and a negative association of stromal caveolin-1 expression with the degree of neoplastic infiltration and BRAF status.
Conclusion. Altered expression of caveolin-1 in the thyroid epithelial and stromal compartments may be involved in the pathogenesis of PTC. The potential clinical significance of caveolin-1 expression, as well as its relation to BRAF mutation status, deserves further investigation.
Keywords caveolin-1, papillary thyroid cancer, immunohistochemistry, BRAF P apillary thyroid cancer (PTC) is the most common type of malignant thyroid tumor, constituting more than 80% of thyroid malignancies. 1 Even though PTC is a welldifferentiated cancer generally with a favorable prognosis, it may become invasive and develop regional metastases in lymph nodes, as well as more distantly. [2] [3] [4] Therefore, there is increasing interest in complementing conventional histopathological evaluation with molecular tools that may enable early diagnosis and recognition of the more aggressive PTC subtypes. One considerably explored molecular marker of PTC aggressiveness is BRAF, a kinase involved in the Ras/MAPK signaling pathway. The most frequent BRAF mutation is V600E, caused by a T1799A transversion, 5 which induces constitutive activation of BRAF, leading to activation of the MAPK pathway, resulting in increased cell proliferation and tumorigenesis. 6, 7 The frequency of BRAF mutation in PTC ranges from 26% to 44%, [8] [9] [10] occurring most often in the classical and tall cell variants. 11 BRAF provides valuable prognostic information as its presence is correlated with more aggressive phenotypes. Different studies have confirmed the association of BRAF mutation with at least 1 prognostic factor, such as extrathyroidal extension, lymph node metastasis (LNM), or advanced tumor stage. [12] [13] [14] [15] [16] [17] Even though several studies have failed to detect correlation of BRAF mutation with aggressive behavior of PTC, [18] [19] [20] the outcome of most studies implicate BRAF mutation as an independent marker for more aggressive PTC.
By activating the Ras/MAPK signaling pathway, BRAF V600E mutation controls a network of genes, thereby contributing to tumor aggressiveness via mechanisms such as cell adhesion, migration, and invasion. Caveolin-1 is a protein that plays an important role in cell movement by mediating tumor cell migration and invasion. [21] [22] [23] To date, there have been no publications discussing potential relationships between caveolin-1 and BRAF in thyroid cancer. Therefore, it remains unknown whether changes in BRAF mutation status can influence caveolin-1 expression in PTC patients.
Caveolin-1, a key component of flask-shaped membrane invaginations called caveolae, is expressed in different cell types, particularly in endothelial cells, fibroblasts, adipocytes, and smooth muscle cells. 24, 25 Caveolin-1 functions as a scaffolding protein in caveolae and is implicated in vesicular transport, cholesterol homeostasis, cell migration, and the regulation of intracellular signaling pathways. [26] [27] [28] In carcinogenesis, this protein can act both as a tumor suppressor and as a tumor promoter. 22 In breast, colon, gastric, and lung cancer, the initial loss of caveolin-1 promotes cell proliferation and reduces apoptosis. In other types of neoplasm, such as prostate cancer, up-regulation of caveolin-1 is correlated with poor prognosis. 29 Caveolin-1 is expressed in thyrocytes under physiological conditions. When compared with normal tissue, upregulation of caveolin-1 in PTC and its down-regulation in follicular thyroid cancer have already been reported, [30] [31] [32] suggesting potential use as a diagnostic marker to differentiate the various histologies of thyroid malignancies (ie, to distinguish papillary from follicular thyroid carcinoma).
We have noted that currently available commercial anticaveolin antibodies may play a useful role in attempts to distinguish some benign from malignant thyroid tumors. 33 However, in that study, caveolin-1 expression was immunohistochemically evaluated only in thyroid follicular epithelial cells. 33 Since caveolin-1 is ubiquitously expressed, we decided to analyze the whole tumor tissue, including both thyrocytes and the stromal compartment. Tumor stroma is composed of cellular components including fibroblasts, myofibroblasts, leukocytes, endothelial cells, and bone marrow-derived cells, as well as an extracellular matrix that provides structural scaffolding for the cells. 34 It is well known that the associated stroma plays an important role in tumor growth, invasion, and metastasis. 35 Therefore, in this study, we evaluated the expression of caveolin-1 in tissue extracts obtained from formalin-fixed PTC samples by Western blot (WB) and compared the findings with the immunohistochemical (IHC) scores for both epithelial and stromal caveolin-1 for the corresponding histological specimens. Furthermore, the results were related to clinicopathological features and the BRAF mutational status of PTCs.
Materials and Methods

Patients and Tissue Samples
All clinical specimens examined in this study were approved by the Ethics Committee at the Center for Endocrine Surgery, Clinical Center of Serbia, Belgrade, and informed consent to use excess biological material for investigative purposes was obtained from all patients participating in the study. Formalin-fixed paraffin-embedded tissues from 49 patients with PTC were collected in the archives of the Clinical Center of Serbia. Cases comprised 16 carcinomas of the classical type, 12 of the follicular type, and 21 rare PTC cases. Among the rare ones, there were 15 solid PTC cases, 3 cases of trabecular PTC, 1 diffuse sclerosing PTC, and 2 Warthin-like PTC. The original whole-section slides and/or recuts were verified by a pathologist to establish diagnosis. Clinicopathological parameters evaluated in this study were age, gender, tumor size, pT status, intraglandular dissemination, LNM, degree of neoplastic infiltration, and chronic lymphocytic thyroiditis. All available clinical data and pathology reports were recorded. Carcinomas were staged in accordance with the American Joint Committee on Cancer tumor node metastasis system. 36 
Western Immunoblotting
Caveolin-1 expression was analyzed in whole-tissue extracts prepared from formalin-fixed and paraffin-embedded tissue blocks. Proteins were extracted using 200 mL RIPA buffer per sample (50 mM Tris pH 8, 150 mM NaCl, 2% SDS, 1% Triton X-100), and the protein concentration was measured using Pierce BCA Protein Assay Kit (Pierce, Rockford, IL).
Immunoblotting was performed using polyclonal rabbit anti-caveolin-1 antibody (sc-894, Santa Cruz Biotechnology Inc, Santa Cruz, CA). Anti-b-actin antibody was used as a loading control (A5441, Sigma-Aldrich, St Louis, MO). Densitometric analysis was done using the Total Lab program. For each sample, the caveolin-1 signal was normalized to b-actin; the same control sample was included in each WB and used for comparison of different blots.
Immunohistochemistry
Immunohistochemistry was performed as described previously, 37 using the same antibody as for WB (sc-894, Santa Cruz Biotechnology Inc).
The tumor sections were simultaneously examined by 2 researchers (with no knowledge of the clinical findings) for staining intensity and distribution of immunoreactivity within a single tissue section. Staining was scored separately for the epithelial and stromal compartments using an empirical semiquantitative system as reported previously 33 : no or focal staining (0), weak (11), moderate (12) , and strong (13) cytoplasmic staining. In cases of disagreement, the observers reexamined the slide together to establish a consensus score.
DNA Isolation
DNA was extracted from eight 10-mm sections using the RecoverAll Total Nucleic Acid Isolation Kit for formalin-fixed paraffin embedding (Ambion, Carlsbad, CA). DNA concentration was quantified by NanoVue (GE Healthcare, Buckinghamshire, UK).
Detection of BRAF Mutation
BRAF mutation was detected by mutant allele-specific PCR amplification (MASA), 38 using 2 forward primers, BRAF_f_a GTGATTTTGGTCTAGCTACAGT and BRAF_f_b GTGA-TTTTGGTCTAGCTACAGA (for wild type and BRAF T1799A transversion mutation, respectively), and a reverse primer, BRAF_r GGCCAAAAATTTAATCAGTGGA. The initial denaturation was carried out at 94°C for 2 minutes, followed by 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds, for 35 cycles.
Statistical Analysis
Differences in caveolin-1 expression between groups were evaluated using the Mann-Whitney U test. Correlation was examined with the Spearman rank-correlation test. All data were analyzed using SPSS 12.0.1 software (SPSS Inc, Chicago, IL) for Windows.
Results
Pathology Report
A summary of the clinicopathological information about the archival surgical thyroid tissue paraffin blocks evaluated here is presented in Table 1 . Thirty cases were more than 45 years of age; the male:female ratio was 1:2.6. The mean tumor size was 32.38 mm. In this data set, all 4 tumor stages were represented, and the distribution of patients was as follows: pT1, 8.1%; pT2, 36.8%; pT3, 44.9%; and pT4, 10.2%, with most of them in stage pT3. We observed tumor dissemination inside the thyroid gland in 21 cases. LNM was identified in 10 cases. According to the degree of neoplastic infiltration, the samples were sorted as follows: A, totally encapsulated tumors (6 cases); B, nonencapsulated tumors without thyroid capsule invasion (11 cases); C, tumors with thyroid capsule invasion (12 cases); and D, tumors with extraglandular invasion (14 of 49), according to Basolo et al. 12 The presence of chronic lymphocytic thyroiditis was observed in 6 cases, and Hashimoto's thyroiditis was diagnosed in 2 patients. The presence of diffuse lymphocytic infiltrate and the formation of lymphoid follicles were the criteria for diagnosing chronic lymphocytic thyroiditis. Hashimoto's thyroiditis was diagnosed by the presence of serum autoantibodies (TgAb, TPOAb). We genotyped the patients for the BRAF V600E mutation, and this was detected in 17 tumor samples.
Caveolin-1 Expression Fluctuates with PTC Variants and Genotype
Total caveolin-1 expression was evaluated by Western blot in tissue homogenates prepared from the series of 49 PTCs (Figure 1) . The highest total caveolin-1 expression was detected in solid PTC, and this was statistically significant when compared with classical PTC (P = .009). If we mark the expression in solid PTC as 100% and downscale the expression in other subtypes accordingly, we observe that caveolin-1 was least expressed in Warthin-like tumors (5.3%), followed by diffuse sclerosing PTC and classical PTC (33.9% and 40.9%, respectively). Follicular PTC (61.6%) and trabecular PTC (64.9%) had approximately the same expression level, slightly more than the previously mentioned variants.
Tissue samples from these patients were additionally analyzed by immunohistochemistry to determine the caveolin-1 expression pattern in particular PTC compartments (ie, in epithelium and stroma). The results of the IHC showed that caveolin-1 reactivity was abundant in the stromal compartments of the investigated PTCs and was higher than in the epithelium (epithelium mean scores: 1.23 for PTCcl, 0.92 for PTCfv, and 0.47 for PTCsol; stromal mean scores: 0.54 for PTCcl, 1.92 for, PTCfv and 1.53 for PTCsol; Table 2 ). However, both stromal and cytoplasmic reactivity were variable in the same histotype. In some cases, caveolin-1 reactivity in either the epithelial or the stromal compartment was missing or was very low. Overall, the neoplastic epithelial compartment showed a decline in caveolin-1 reactivity from classical via follicular to solid PTC, and almost no reaction was observed in trabecular PTC and Warthin-like type carcinoma (Table 2; Figure 2) . Thus, the immunoreactivity of caveolin-1 in epithelium and in stroma was influenced by the PTC subtype.
When we investigated the correlations between the total caveolin-1 content by WB and caveolin-1 IHC scores in the epithelial and stromal cells, we found a positive relationship between the WB results and stromal IHC scores (r = 0.311, P = .038, Spearman correlation test). On the other hand, total caveolin-1 levels were not associated with the immunohistochemically detected caveolin-1 scores for the epithelial tumor cells (r = 0.03, P = .847, Spearman correlation test). Moreover, when we investigated correlations between the immunoreactivity scores in the epithelial and stromal cells, we found a slight inverse trend but without statistical significance (r = 20.004, P = .979, Spearman correlation test).
Since the BRAF V600E mutation is a genetic event characteristic for PTC, we genotyped the patients and detected this mutation in 17 cases: 13 classical PTC, 2 follicular PTC, 1 diffuse sclerosing PTC, and 1 Warthin-like PTC. The levels of caveolin-1 expression obtained by WB (normalized values) were compared in PTC samples with and without the mutation. The results showed down-regulation of caveolin-1 expression in patients with the V600E mutation (Figure 3) , which was statistically significant when compared with samples with wild-type BRAF (P = .023).
Relation between Caveolin-1 Protein Expression and Clinicopathological Features of PTC Including BRAF Mutation Status
Caveolin-1 expression was analyzed statistically for WB quantification and IHC scoring in relation to each of the 9 parameters. Table 1 gives Spearman correlation coefficients among the caveolin-1 levels (total, epithelial, and stromal) and the clinicopathological characteristics of the PTC patients.
In this selected population, there was no association between caveolin-1 expression (either total, epithelial, or stromal) and the following clinicopathological data: age, gender, tumor size, pT status, and intraglandular tumor dissemination.
However, we found a positive correlation between epithelial caveolin-1 expression and LNMs (r = 0.299, P = .044). When we grouped the samples according to the degree of neoplastic infiltration (as detailed in the Materials and Methods section), there was a significant negative association between the level of stromal caveolin-1 expression and the depth of tumor infiltration (r = 20.339, P = .033). In addition, the expression of total caveolin-1 was significantly different in patients with chronic lymphocytic thyroiditis compared with patients without thyroiditis (r = 20.353, P = .015). BRAF mutation status correlated significantly with total and stromal caveolin-1 expression; that is, BRAF mutated PTC cases showed significantly lower expression of caveolin-1 protein (r = 20.327, P = .022, and r = 20.375, P = .010, respectively).
Discussion
Until now, only scanty data have been reported on the IHC evaluation of caveolin-1 content in thyroid cancer with conflicting results. [30] [31] [32] 39 In addition, the relationship between total caveolin-1 levels in tumor tissue and IHC staining for caveolin-1 in epithelial and stromal compartments has not been examined. In this study, we analyzed the expression of caveolin-1 in PTC using WB and IHC and related these findings with several clinicopathological features of PTC and BRAF mutational status. In our series, total caveolin-1 levels were not related to immunohistochemically detected caveolin-1 expression level in epithelial tumor cells. On the other hand, a positive association was found for the stromal compartment, indicating that stromal caveolin-1 mainly contributes to the total caveolin-1 content in tumor extracts. In addition, an inverse correlation was observed between the caveolin-1 level in stroma and epithelium but without statistical significance. This indicates considerable individual variations in epithelial and stromal expression of caveolin-1, even within the same subtype. Alterations in caveolin-1 gene expression during malignant transformation of thyroid cells are not yet understood.
Caveolin-1 expression in thyrocytes was analyzed by Ito et al, 32 who reported up-regulation in PTC compared with normal tissue but down-regulation with dedifferentiation of thyroid cancer. In our series, caveolin-1 immunostaining of thyrocytes was more intense in classical PTC than in the other PTC variants (follicular, solid, trabecular). Thus, caveolin-1 expression in both epithelium and stroma is influenced by the histologic growth pattern of PTC, which has not been pointed out previously.
The results of WB and immunohistochemical staining for caveolin-1 were also correlated with some clinicopathological parameters of the PTC patients. We found a significant positive relationship between epithelial expression of caveolin-1 and the presence of LNM in PTC. Thus, it could be suggested that up-regulation of caveolin-1 expression in thyrocytes coincides with lymphatic spreading of tumor cells.
As far as stromal caveolin-1 expression was concerned, it was negatively associated with the depth of tumor infiltration; that is, lower levels of caveolin-1 were detected in tumors with extraglandular invasion, indicating a trend for caveolin-1 down-regulation during the progression of tumor infiltration.
Over the past few years, it has become obvious that the stromal component acts not only as a matrix surrounding cancer cells but also plays an integral role in cancer progression. 40 The role of stromal expression of caveolin-1 has been extensively studied in breast cancer. 41 Thus, Lisanti and colleagues 40 revealed that caveolin-1 down-regulation in stroma correlates with a worse cancer prognosis. The loss of stromal caveolin-1 in breast cancer is also associated with advanced tumor and nodal stages, early tumor recurrence, LNM, and poor clinical outcome. 41, 42 In prostatic cancer, loss of caveolin-1 in tumor-associated stromal cells has been related to a high Gleason score, that is, a worse prognosis. 43 With regard to thyroid carcinoma, there is a single recent report on stromal caveolin-1 by Kim et al, 39 in which no significant association of caveolin-1 expression with any clinicopathological parameters was found. This conflict with our results could be due to different factors, including the heterogeneity of tumor types, the use of different antibodies, or the somewhat underpowered series, among others.
Our WB results, which reflect the total caveolin-1 content in tumor tissue, showed statistically significant negative correlations of caveolin-1 content with persistence of chronic lymphocytic thyroiditis and the presence of the V600E BRAF mutation. Down-regulation of total caveolin-1 coincides with thyroiditis, probably because lymphocytes occupy a large area of thyroid tissue but do not stain for caveolin-1. When the caveolin-1 expression was identified as epithelial and stromal, the significance of this correlation was lost, confirming our assumption that the immunonegativity of inflammatory cells contributed to the decreased overall caveolin-1 content in cases of chronic lymphocytic thyroiditis. An interesting result in the current investigation was down-regulation of both total and stromal expression of caveolin-1 in PTC cases in the presence of BRAF mutation. Several studies have confirmed that the occurrence of BRAF mutation in PTC correlates with LNM, extrathyroidal extension, advanced tumor stage, and tumor recurrence, 9, 10, 44, 45 pointing to BRAF mutation as a factor that predicts poorer prognosis. In our study, of 17 patients who tested positive for BRAF mutation, 12 had extrathyroidal extension and 8 had LNM. To our knowledge, this is the first report on correlation of caveolin-1 expression with the BRAF mutation status of PTC. These data are too preliminary to conclude whether caveolin-1 and BRAF are 2 independent prognostic markers or the levels of caveolin-1 are indeed diminished by BRAF V600E mutation via MAPK pathway activation. Thus, the possible influence of BRAF mutation on regulation of caveolin-1 gene expression should be further investigated using more sophisticated molecular approaches.
Conclusions
Altered expression of caveolin-1 in thyroid epithelial and stromal cells is influenced by the histologic growth pattern of PTC and may be involved in the pathogenesis of PTC. Upregulation of caveolin-1 in thyroid epithelia correlated with LNM, while down-regulation of caveolin-1 in the stromal compartment correlated with the degree of neoplastic infiltration. Both total and stromal down-regulation of caveolin-1 coincided with BRAF mutation. The potential clinical significance of caveolin-1 expression as well as its relation to BRAF mutation status deserves further investigation.
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